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Office of Evidence Based Practice – Specific Care Question: Ototopical Quinolones versus Aminoglycosides
Specific Care Question: Should ototopical quinolones versus ototopical aminoglycosides be used in the treatment of suppurative otitis media and acute otitis
externa in patients with perforated tympanic membranes to prevent ototoxicity while maximizing clinical cure rate?
Question Originator: Keith Mann MD, MEd
Plain Language Summary from The Office of Evidence Based Practice:
In both suppurative otitis media and acute otitis externa the use of ototopical aminoglycosides are not recommended for the use in children with perforated
tympanic membranes (Up to date, 2015). The American Academy of Otolaryngology-Head and Neck Surgery (Rosenfeld et al., 2013) does not recommend the
use of aminoglycosides in children with otitis media or tympanostomy tubes or any kind of perforated tympanic membranes. This recommendation is also
supported by position statements from the New Zealand and Australian Societies of Otolaryngology Head and Neck Surgery (Black et al., 2007; Gilbert, Dawes,
Mahadevan, Baber, & Hall, 2007).
Ototoxicity is damage to the hearing or balance functions of the ear by drugs or chemicals.The ototoxic effects of systemic aminoglycosides are well documented
(Ariano, Zelenitsky, & Kassum, 2008). However, the relationship of ototoxicity with topical aminoglycoside treatment is not as strong and is based on cases
studies of patients with chronic otitis media (Phillips, Yung, Burton, & Swan, 2007). Topical aminoglycosides are potentially ototoxic, especially when the middle
ear is exposed, as is the case with tympanostomy tubes (Daniel et al., 2005). Although the incidence is low, aminoglycoside ototoxicity with ear drops has been
reported in 1 in 10,000 patients treated (Roland et al., 2004).
The American Academy of Otolaryngology-Head and Neck Surgery (Rosenfeld et al., 2014) recommends non-ototoxic topical preparations be used when a patient
has a known or suspected perforation of the tympanic membrane. Quinolones are the only antibiotic approved by the FDA for otitis media and otitis externa with
perforated tympanic membranes including tympanostomy tubes (FDA, 2005; Kutz Jr, Roland, & Lee, 2013).
Harris, Elhassan, & Flook (2016) reported in a systematic review of nine randomized controlled trials that first line treatment for chronic suppurative otitis media
with ototopical quinolones is equivocal or better than aminoglycosides, has not been shown to have the same risk for ototoxicity, and represents a safe and
effective treatment alternative.
Recommendation from this review:
1) Based on very low quality evidence and best practice, aminoglycosides should not be used in the treatment of patients with suppurative otitis media and
otitis externa with perforated tympanic membranes due to the increase the risk of ototoxicity.
2) Based on very low quality evidence ototopical quinolones should be used in the treatment of patients with suppurative otitis media and otitis externa with
perforated tympanic membranes including tympanostomy tubes. Ototopical quinolones are just as efficacious as ototopical aminoglycosides in the
treatment of suppurative otitis media.
3) Based on best practice recommendations from The American Academy of Otolaryngology-Head and Neck Surgery and very low quality evidence,
ototopical quinolones should be used in the treatment of patients with suppurative otitis media and acute otitis externa with perforated tympanic
membranes including tympanostomy tubes. Ototopical quinolones are just as efficacious as ototopical aminoglycosides in the treatment of otitis externa.
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Literature Summary:
Otitis Media
Ototoxic Effects. A clinical practice guideline on tympanostomy tubes in children by The American Academy of Otolaryngology- Head and Neck Surgery
(Rosenfeld et al., 2013) recommends only the use of topical drops approved for use with tympanostomy tubes to avoid potential ototoxicity from aminoglycosidecontaining eardrops. AGREE II was used to grade and evaluate this guideline (Brouwers et al., 2010). The guideline was recommended for use by the authors of
this synthesis based on the overall high quality of the guideline.
An evidence review and consensus report by the Ear Nose and Throat – United Kingdom (Phillips et al., 2007) found twelve retrospective case reports or case
series and six prospective trials of potential ototoxicity as a consequence of topical aminoglycoside administration. Phillips reported that for such a rare
complication, a large sample size would be needed to detect this complication. In the twelve case reports and case series, Phillips et al. (2007) reported 76 cases
of ototoxicity because of topical aminoglycoside drops (number of patients in the studies = 85). In the six prospective trials 16 patients were reported with
ototoxicity (number of patients in the studies = 737). In the meta-synthesis, there was a high level of inconsistency identified in the variable doses and a variety
of ototopical agents.
Clinical Cure Rate. Harris et al. (2016) reported in a systematic review of nine randomized control trials that the first line treatment of chronic suppurative
otitis media with quinolones is equivocal or better than aminoglycosides and has not been shown to have the same risk for ototoxicity. A meta-analysis was not
performed for cure rate due to the high level of heterogeneity among the nine studies. Two studies of the systematic review showed a higher clinical cure rate
with quinolones compared to aminoglycosides (Tong & Woo, 1996; Couzos, Lea, Mueller, Murray, & Culbong 2003); Tong and Woo (1996) showed significantly
more patients treated with quinolones had resolution of otorrhea compared to those treated with aminoglycosides (93% versus 71%, p= 0.04). Couzos, Lea,
Mueller, Murray, and Culbong (2003) compared quinolones versus aminoglycosides in a pediatric aboriginal population and found a cure rate of 76.4 versus 51.8
percent, respectively (p= 0.009), with an absolute difference of 24.6%, 95% CI [15.8-33.4]. Three studies showed no difference in cure rate (Brodsky, BenDavid, Srugo, Larboni, & Podoshin, 1997; Leach, Wood, Gadil, Stubbs, & Morris, 2008; Miró, 2000). In all the studies only one patient was reported as having a
significant change in pure tone audiometry values (Miró, 2000). Two studies reported a statistically significant difference in cure rate in favor of quinolones but
the quality of the studies was downgraded as they were not blinded and neither published specific data or clinical outcomes (Nawasreh & Fraihat, 2001; Tutkun et
al., 1995). The two studies that compared quinolones and aminoglycosides for post-tympanostomy prophylaxis did not show a statistically significant difference in
number of infections between the groups (Morpeth, Bent, & Watson, 2001; Poetker et al., 2006).
Otitis Externa
Ototoxic Effects. A clinical practice guideline on acute otitis externa by The American Academy of Otolaryngology- Head and Neck Surgery (Rosenfeld et al.,
2014) recommends clinicians should prescribe a non-ototoxic preparation when the patient has a known or suspected perforation of the tympanic membrane,
including a tympanostomy tube. The recommendation is based on extrapolation of animal studies and a small number of direct evidence in patients (Rosenfeld et
al., 2014). The guideline reports that hearing loss is not likely to occur with one dose but severe hearing loss has been observed after prolonged or repetitive
administration of topical aminoglycosides (Abello, Vinas, & Vega, 1997; Winterstein, Liu, Xu, & Antonelli, 2013). AGREE II was used to grade and evaluate this
guideline (Brouwers et al., 2010). The guideline was recommended for use by the authors of this synthesis based on the overall high quality of the guideline.
A Cochrane review on interventions for acute otitis externa (Kaushik, Malik, & Saeed, 2010) recommends against the use of topical aminoglycoside when patients
have perforated tympanic membranes but none of the studies included in the Review reported ototoxicity as an outcome.
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Clinical Cure Rate. A Cochrane review on interventions for acute otitis externa (Kaushik, Malik, & Saeed, 2010) identified only one study (n=54) that
compared topical quinolone antibiotics versus aminoglycosides for otitis externa. It showed no clinical difference in cure rates between topical quinolone
antibiotics versus aminoglycosides OR = 1.71, 95% CI [0.4, 7.23]. Kaushik et al. (2010) reported that the choice of topical intervention does not appear to
influence the therapeutic outcome significantly. In addition, Kashik, Malik and Saeed (2010) identified that most topical treatments are equally effective, and the
treatment used should be determined by other factors, such as risk of ototoxicity, contact sensitivity, developing resistance, availability, cost, and dosing schedule.
EBP Scholar’s responsible for analyzing the literature:
Jennifer Foley, RT(R)(N), CNMT
Kori Hess, PharmD
Jeanette Higgins, RN, MSN, CPNP
Anne Holmes, RN, MSN, MBA-HCM, CCRC
David Keeler, RN, BSN, CPN
Helen Murphy, BHS RRT AE-C
Robert Rhodes, MHA, RRT-NPS
EBP team member responsible for reviewing, synthesizing, and developing this literature:
Jarrod Dusin MS, RD, LS, CNSC
Search Strategy and Results:
PubMed
("Aminoglycosides"[Mesh] OR aminoglycoside* OR "Quinolones"[Mesh] OR quinolone*) AND ("Otitis Media, Suppurative"[Mesh] OR ("otitis media" AND
(discharg* OR purulent OR suppurative))) AND ("Tympanic Membrane Perforation"[Mesh] OR "Middle Ear Ventilation"[Mesh] OR ((tympan* OR "middle
ear" OR eardrum*) AND (perforat* OR ventilat* OR tube OR tubes)) OR grommet*)
Ovid Medline
(Aminoglycosides/ OR Quinolones/) AND (Otitis Media, Suppurative/) AND (Tympanic Membrane Perforation/ OR Middle Ear Ventilation/)
CINAHL
((MH “Aminoglycosides”) OR (MH “Antiinfective Agents, Quinolone”)) AND ((MH “Middle Ear Ventilation”) OR (MH “Tympanic Membrane Perforation”))
AND (MH “Otitis Media”)

Studies included in this review:

Harris, A., Elhassan, H., & Flook, E. (2016). Why are ototopical aminoglycosides still first-line therapy for chronic suppurative otitis media? A systematic review
and discussion of aminoglycosides versus quinolones. The Journal of Laryngology & Otology, 130(01), 2-7.
Kaushik, V., Malik, T., & Saeed, S. R. (2010). Interventions for acute otitis externa. The Cochrane Library.
Phillips, J., Yung, M., Burton, M., & Swan, I. (2007). Evidence review and ENT‐UK consensus report for the use of aminoglycoside‐containing ear drops in the
presence of an open middle ear. Clinical Otolaryngology, 32(5), 330-336.
Rosenfeld, R. M., Schwartz, S. R., Cannon, C. R., Roland, P. S., Simon, G. R., Kumar, K. A., . . . Robertson, P. J. (2014). Clinical Practice Guideline Acute Otitis
Externa. Otolaryngology--Head and Neck Surgery, 150(1 suppl), S1-S24.
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Rosenfeld, R. M., Schwartz, S. R., Pynnonen, M. A., Tunkel, D. E., Hussey, H. M., Fichera, J. S., . . . Haskell, H. (2013). Clinical practice guideline tympanostomy
tubes in children. Otolaryngology--Head and Neck Surgery, 149(1 suppl), S1-S35.

Studies not included in this review with rationale for exclusion:

Venekamp, R. P., Sanders, S., Glasziou, P. P., Del Mar, C. B., & Rovers, M. M. (2013). Antibiotics for acute otitis media in children. The Cochrane Library. – No
recommendations made on the type of antibiotics.
Agro, A. S., Garner, E. T., Wright, J. W., de Escobar, I. C., Villeda, B., & Seidlin, M. (1998). Clinical trial of ototopical ofloxacin for treatment of chronic suppurative
otitis media. Clinical therapeutics, 20(4), 744-759. – Control of current practice medication not specified.
Macfadyen, C. A., Acuin, J. M., & Gamble, C. L. (2005). Topical antibiotics without steroids for chronically discharging ears with underlying eardrum perforations.
The Cochrane Library. – Topical versus systemic antibiotics.
Method Used for Appraisal and Synthesis:
The Cochrane Collaborative computer program, Review Manager (RevMan 5.3) was used to synthesize nine included studies. AGREE II was used to assess the
quality of the two included guidelines. GRADEpro GDT (Guideline Development Tool) is the tool used to create Summary of Findings Tables for this analysis.
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Table 1
Question: Should ototopical quinolones versus ototopical aminoglycosides be used in the treatment of suppurative otitis media and acute otitis externa in
patients with perforated tympanic membranes to prevent ototoxicity while maximizing clinical cure rate?
Included Study: Phillips, Yung, Burton, & Swan, 2007
Quality assessment
№ of
studies

Study design

Risk of
bias

Inconsistency

Indirectness

Imprecision

Impact

Quality

An evidence review found 18 studies.
Twelve retrospective case reports or
case series and six prospective trials of
potential ototoxicity as a consequence
of topical aminoglycoside
administration. The author reported
that for such a rare complication, a
large sample size would be needed to
detect this complication. The twelve
case reports and case series, reported
76 cases of ototoxicity because of
topical aminoglycoside drops (number
of patients in the studies = 85). In the
six prospective trials 16 patients were
reported with ototoxicity (number of
patients in the studies = 737). In the
meta-synthesis, there was a high level
of inconsistency identified in the
variable doses and a variety of
ototopical agents.

⨁◯◯◯
VERY
LOW

Other
considerations

Importance

Ototoxicity - Suppurative Otitis Media
18

observational
studies

not
serious

very serious

1

not serious

very serious

2

none
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Table 2
Question: Should ototopical quinolones versus ototopical aminoglycosides be used in the treatment of suppurative otitis media and acute otitis externa in
patients with perforated tympanic membranes to prevent ototoxicity while maximizing clinical cure rate?
Included Study Harris, Elhassan, & Flook, 2016
Quality assessment
№ of
studies

Study design

Risk of
bias

Inconsistency

Indirectness

Imprecision

Impact

Quality

A meta-analysis of all nine studies was
not created for cure rate due to the
high level of heterogeneity between
studies. Two studies showed a higher
clinical cure rate with quinolones
compared to aminoglycosides. One
study showed patients treated with
quinolones had resolution of otorrhoea
compared to those treated with
aminoglycosides (93 percent vs. 71
percent, p= 0.04). One study
compared quinolones to
aminoglycosides in a pediatric
aboriginal population and found a cure
rate of 76.4 versus 51.8 percent
respectively (p= 0.009, absolute
difference of 24.6%, 95% confidence
interval (95% CI [15.8-33.4%]). Three
studies showed no difference in cure
rate The two studies that compared
quinolones and aminoglycosides for
post-tympanostomy prophylaxis did
not show a statistically significant
difference in number of infections
between the groups.

⨁◯◯◯
VERY
LOW

Other
considerations

Importance

Cure Rate - Suppurative Otitis Media
9

randomized
trials

serious
3,4,5

very serious

1,6

serious

7

not serious

none
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CI: Confidence interval
1.
2.
3.
4.
5.
6.
7.

Many of the studies used variable doses and a variety of ototopical agents.
Outcome is rare and a large number of patients is required to see effect.
Random sequence generation not reported by 4 of the 9 studies
Allocation concealment not done or reported by 4 of the 9 studies
Blinding not done or reported by 4 of the 9 studies
High level of heterogeneity
Some of the studies did not report patient demographics
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Figure 1
Risk of bias table
Included Study Harris, Elhassan, & Flook, 2016
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Couzos 2003

Methods
Participants

Community based, multicenter, double-blind, randomized control trial
Setting: Eight (8) Aboriginal Communities in northern Western Australia and Queensland
between 1 April 2001 and 30 June 2002.
Randomized into study: N = 147
("The strict inclusion criteria resulted in slower recruitment than predicted, and the trial was
stopped because of resource constraints before achieving the intended sample size.")
 Group 1: ciprofloxacin (CIP) = 75
 Group 2: framycetin, gramicidin, dexamethasone (FGD) = 72
Completed Study: N = 111
 Group 1: CIP = 55
 Group 2: FGD = 56
Inclusion Criteria:
 Children age less than 15 years
 At least 2 weeks of otorrhea
 Tympanic membrane perforation
Exclusion Criteria:
 Current febrile illness
 Current antibiotic use
 Antibiotic use in the previous two weeks
 Allergy to ototopical medications
 Specific allergy to fluoroquinolones
 Need for renal dialysis
 Recent ear surgery
 An in-situ grommet or tympanostomy tube
 Mastoid surgery in the last 12 months
 Congenital ear or hearing problems
 Obstructed middle ear (polyp)
 Pregnancy
 Unlikely to stay in the study region for follow-up
Power Analysis: 100 children were needed in each treatment arm to detect an improvement in
resolution of CSOM from 50% to 70% with a power of 80% at a level of 5 %. To allow for a 30%
loss to follow-up, 300 children were needed (30–60 per recruitment site).

Interventions

Group 1: ciprofloxacin (o.3%, Ciloxan, Alcon Labs Pty Ltd)
Group 2: framycetin (0.5%), gramicidin, and dexamethasone (Sofradex, Aventis Pharma Pty Ltd)
 Each group received 5 drops twice daily for 9 days
 Each child was assessed daily
 Ears were cleaned prior to delivery of medication with 0.5% povidone-iodine solution
 Swimming was not permitted
 Half of the treatments were given by health care workers
 Second half of treatments given by parents after instruction on proper application
If clinical cure was achieved by Day 10, treatment was stopped and reassessed on Day 14

Outcomes

Primary Outcomes:
 The proportion of children with clinical cure.
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Secondary Outcomes:
 The proportion of children with healed perforated tympanic membranes
o (one-step or two-step decrement in size of the perforation or complete healing)
 The proportion of children with improved hearing.
o (reduced thresholds compared with baseline)
Notes

A clinical cure was defined as a complete absence of discharge in the middle ear and canal
determined by otoscopy.
All recruitment, treatment, and clinical assessment was conducted by trained Aboriginal Health
Workers (AHWs) at each participating ACCHS. Most workers had previously completed the
Commonwealth-sponsored training program by Australian Hearing.22 Acquisition of skills in
otoscopy, video otoscopy/photography capture, and audiometry during training were audited by
Australian Hearing. All sites had calibrated screening audiometers (Welch Allyn, Skaneateles Falls,
NY), soundproof rooms, and otoscopy and video otoscopy equipment.

Risk of bias table
Scholar’s
judgment

Bias

Support for judgment

Random sequence generation
(selection bias)

Low Risk

a statistical program used to generate balanced random
sequences for each site to assign the two ototopical medications
to a list of client identification numbers

Allocation concealment (selection
bias)

Low Risk

participants were then assigned a client number according to the
sequence, which was concealed from patients and investigators

Blinding of participants and
personnel (performance bias)

Low Risk

Blinding of outcome assessment
(detection bias)

Low Risk

investigators were blinded
to achieve blinding, third parties handled and transferred the
medications to clinics

Incomplete outcome data (attrition High Risk
bias)

Patients enrolled, but did not complete the follow-up schedule.
"intention to treat" analysis not completed

Selective reporting (reporting bias) Low Risk

outcomes reported as described

Other bias

conclusions based off a sub-acceptable population size

High Risk

Fradis 1997
Methods
Participants

Randomized, double-blind, placebo-controlled
Setting: otolaryngology department outpatient clinic at a university teaching hospital from Jan
1994 - Dec 1995
Randomized into study: n = 60 ears (51 patients)
 Group 1: ciprofloxacin n = 20 ears
 Group 2: tobramycin n = 20 ears
 Group 3: placebo (1% burrow aluminum acetate) n = 20 ears
Completed study: n = 54 ears (45 patients)
 Group 1: ciprofloxacin n = 19 ears
 Group 2: tobramycin n = 18 ears
 Group 3: placebo n = 17 ears
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Gender, males:
 Group 1: 9
 Group 2: 15
 Group 3: 10
Age, years (mean):
 Group 1: 19-70 (40.8)
 Group 2: 18-70 (45)
 Group 3: 18-73 (47.4)
Inclusion Criteria: diagnosis of chronic otitis media (not specifically defined)
Exclusion Criteria: patients < 18 yrs. with history of middle ear operation, suspicion of
cholesteatoma, allergy to aminoglycosides or fluoroquinolone derivatives, or "general health
problems"
Power Analysis: not discussed
Interventions

Outcomes

Notes

Patients were randomized to 1 of 3 treatment groups:
 Group 1: ciprofloxacin 5 drops in affected ear 3 times daily for 3 weeks
 Group 2: tobramycin 5 drops in affected ear 3 times daily for 3 weeks
 Group 3: placebo 5 drops in affected ear 3 times daily for 3 weeks
Primary Outcome Measures:
 Cessation of otorrhea
o Group 1: cure 9 (47%), improvement 6 (31%), failure 4 (21%); p = 0.02 for
group 1 vs. 3
o Group 2: cure 10 (55%), improvement 3 (16.7%), failure 5 (28%); p = 0.06 for
group 2 vs. 3
o Group 3: cure 4 (35%), improvement 3 (18%), failure 10 (60%)
 Eradication of microorganisms in post-treatment cultures
o Group 1: eradication 10 (67%), persistence 2 (13%), super infection 3 (20%)
o Group 2: eradication 8 (67%), persistence 3 (25%), super infection 1 (8.3%)
o Group 3: eradication 2 (20%), persistence 3 (30%), super infection 5 (50%)
Toxicity was not reported in this study.
Bacteria was generally susceptible to antibiotics:
 pseudomonas most common (46%) with 94% sensitivity to ciprofloxacin and 70%
sensitivity to tobramycin
 staph aureus second most common (24%) with 78 % sensitivity to ciprofloxacin and
100% sensitivity to tobramycin

Risk of bias table
Bias

Scholar’s
judgment

Random sequence generation
(selection bias)

Unclear Risk

Allocation concealment (selection
bias)

Low Risk

Support for judgment
not specifically described but states patients were “assigned
treatment in a randomized manner”
similar appearing containers dispensed from central pharmacy
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Blinding of participants and
personnel (performance bias)

Low Risk

Blinding of outcome assessment
(detection bias)

Low Risk

double-blind, participants and investigators unlikely to observe a
difference in solutions
container code was not broken until after study completion

Incomplete outcome data (attrition High Risk
bias)

6 patients lost to follow-up

Selective reporting (reporting bias) Low Risk

outcomes reported as expected

Other bias

unclear

Unclear

Leach 2008
Methods
Participants

Randomized, assessor-blinded, controlled trial
Setting: 3 remote Aboriginal communities between November 2001 and December 2001
Randomized Into Study: N = 97
 Group 1: ciprofloxacin (CIP) n = 50
 Group 2: framycetin-gramicidin-dexamethasone (FGD) n = 47
End of therapy clinical assessments
 Group 1: 45
 Group 2: 44
Microbiologic assessments
 Group 1: 44
 Group 2: 43
Subsequent follow-up assessments
 Group 1: 47
 Group 2: 43
Gender, males (%):
 Group 1: CIP = 17 (34)
 Group 2: FGD = 20 (43)
Age, years (SD):
 Group 1: CIP n = 3.2 (7.7)
 Group 2: FGD n = 3.7 (7.8)
Inclusion Criteria:
 Aboriginal children 1-16 years of age with chronic tympanic membrane perforation
Exclusion Criteria:
 Allergy to ciprofloxacin(CIP) or framycetin-gramicidin-dexamethasone (FGD)
 Pregnant or breastfeeding
 Diagnosed with cholesteatoma
 Previously treated with tympanoplasty
 Suffering from any other medical condition that could interfere with participation in the
study
Power Analysis:
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Interventions
Outcomes

102 needed to provide 80% power (α 0.05) to detect a 25% reduction in failure to
resolve otorrhea in the CIP group compared with the FGD group.

Group 1: 4 drops CIP twice a day
Group 2: 4 drops FGD twice a day
Primary Outcome: Clinical failure at the end of therapy (otoscopic signs of otorrhea in the canal
or middle ear space, including otorrhea in the canal despite healing of the tympanic membrane.
 The primary outcome assessment occurred in the last 2 weeks of the school term.
Secondary Outcomes:
 Failure to improve otorrhea (from either profuse/moderate to scant or scant to none);
 Failure to heal perforation;
 Mean change in perforation size;
 Failure to resolve discharge at follow up (4–20 weeks after completion of intervention
period);
 Hearing loss at end of therapy—mean pure tone average threshold, and proportion with
mean hearing loss 25 dB (within 6 months after completion of intervention period)


Notes

Ototoxicity was not an outcome measured in this study, but no differences were found in
conductive hearing loss or development of significant sensor neural hearing loss in the
FGD group compared with CIP group.

Risk of bias table
Scholar’s
judgment

Bias

Support for judgment

Random sequence generation
(selection bias)

Low Risk

Allocation concealment (selection
bias)

Low Risk

Blinding of participants and
personnel (performance bias)

High Risk

Blinding of outcome assessment
(detection bias)

Low Risk

Assessors were blinded and assessment of primary outcome were
performed by an outside assessor reviewing video otoscopy.
Secondary outcome assessors blinded to allocation status.

Incomplete outcome data
(attrition bias)

Unclear Risk

Primary outcome reporting is unclear since the end of therapy
assessments (completed) are less than the reported number of
participants for the cure rate between groups.

Randomization of participants by Stata Version 7.0
Allocation sequence concealed throughout study.
Participants were not blinded

Selective reporting (reporting bias) Low Risk
Other bias

Study protocol not available but the published reports include all
expected outcomes.

Unclear Risk

Miro 2000
Methods
Participants

prospective, randomized, open, comparative, multi-center, clinical trial
Setting:16 centers in Spain with ENT physicians serving as PIs
Randomized into Study: N=322,
 Ciprofloxin 0.2% solution (CIP)=168 (52%) study drug
If you have questions regarding this Specific Care Question – please contact
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Polymyxin B, neomycin, and hydrocortisone suspension (PNH)=154 (48%) control
medication

Completed study: Per protocol N=232, CIP=119 (51%), PNH=113 (49%)
Age: CIP=44 (14-70) PNH=45 (14-71)
Gender: males: CIP=79% PNH=63%
Inclusion Criteria:
 Either sex, 14-71 yrs old, capable of following investigator's instructions, chronic
suppurative otitis media (CSOM) defined as serous, mucous, mucopurulent, or purulent
otorrhea, a history of persistent tympanic perforation or the presence of a tympanostomy
tube along with the current episode lasting for at least 6 weeks; and bacteriologic
confirmation of ear infection. Patients presenting with mucopurulent or purulent
discharge were enrolled, irrespective of the culture results. Subjects with persistent ear
infection despite topical or systemic antibacterial therapy could be enrolled after a 72hour washout period.
Exclusion Criteria:
 Acute otitis externa, fungal otitis, otorrhea associated with the presence of
cholesteatoma, presence of severe otalgia or fever greater than 38°C, infection requiring
systemic therapy, participation in another clinical trial in the previous 30 days,
contraindication to the study drugs, pregnancy or suspected pregnancy and absence of
contraceptive measures.
Power Analysis:
 The sample size was estimated to be 360 randomized patients (180 per treatment
group). Power curves were obtained for this sample size according to the formulas of
Machin and Campbell. This sample size ensures a power of at least 80% in any case of
observed cure rates of at least 65% and rates of valid patients
not higher than 30%.
Interventions

Study drug group
 (CIP)=ciprofloxacin sterile and preservative-free 0.2% solution, supplied in 0.5-mL singledose containers (Laboratories Vita, SA, and Química Farmacéutica Bayer, SA), 0.5 mL
twice daily for 10 days (valid interval 6-12 days)


Outcomes

(PNH)=polymyxin B sulfate, neomycin, and hydrocortisone suspension, supplied in
multiple-dose containers (Otosporin; Gayoso Wellcome, SA), 3 drops (0.15 mL) 4 times
daily for 10 days (valid interval 6-12 days).

Cure:
 108 of 119 (91%) patients in the CIP group and 98 of 113 (87%) patients in the PNH
group were cured at visit 2.
 The 90% confidence interval of the observed difference in clinical cure rates between
PNH and CIP (–4%) yielded a lower limit of –8.86% and an upper limit of 4.8%, both of
which were below the maximum value of 15% that defined therapeutic equivalence.
Hearing loss:
 No changes in the audiometric assessment were recorded in the CIP group.
 One patient in the PNH group evolved from a normal audiogram at visit 1 to hearing loss
at all frequencies at visit 3.
Ototoxicity:
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Notes



One participating site included pK levels in the study and drew blood samples, but these
results are not reported in this article.



Clinical success was observed in 91% and 87% of the CIP and PNH-treated patients,
respectively.
At 1-month follow-up, 4% of CIP and 6% of PNH patients showed a relapse of otorrhea.
Bacteriologic eradication was seen in 89% and 85% of patients in the CIP and PNH
groups, respectively.
At 1-month follow-up, reinfection or recurrence of infection appeared in 3 patients in the
PNH group and in 1 patient in the CIP group.
Both treatments were well tolerated.
Hearing loss was not included as a forest plot because they only reported that only one
patient had a hearing loss at visit one in all frequencies.







Risk of bias table
Scholar’s
judgment

Bias
Random sequence generation
(selection bias)

Unclear

Allocation concealment (selection
bias)

High Risk

Blinding of participants and
personnel (performance bias)

High Risk

Blinding of outcome assessment
(detection bias)

Unclear Risk

Support for judgment
Reported as randomly allocated. Not stated how allocated.
open-label
not blinded

Incomplete outcome data (attrition High Risk
bias)

not reported
Per protocol analysis

Selective reporting (reporting bias) High Risk

clear outcomes are not reported although it is implied by data
reported that cure rates bacteriologic results are what they looked
at

Other bias

Unclear if there is other bias

Unclear Risk

Morpeth2001
Methods
Participants

Double-blinded randomized prospective trial
Setting: Medical College of Georgia between April 17, 1997 and May 5, 1998.
Randomized into study: N=100
 Group 1 (ciprofloxacin) n=50
 Group 2 (cortisporin) n=50
Completed study: not given
Gender, males: n= 57
 Group 1 (not given)
 Group 2 (not given)
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Age, years (mean):
 Group 1
o 12 months or less n=10.2
o 13-24months n=15.8
o 25-36months n=29.6
o 3 years or greater n=4.3
 Group 2
o 12 months or less n=10.7
o 13-24months n=17.4
o 25-36months n=29.9
o 3 years or greater n=6.4
o
Inclusion Criteria:
 Children aged 6 months to 11 years
 Diagnosis of chronic otitis media with effusion (COME) (persistent effusion >3 months
with a 20dB conductive hearing loss or recurrent acute otitis media (RAOM) (greater than
4-6 episodes of acute otitis media per year) undergoing myringotomy and tube insertion
at the institution.
Exclusion Criteria:
 patients with COME with preexisting medical conditions that predispose them to COME
o abnormal anatomy
o undergoing other concurrent procedures
 patients who had previously undergone myringotomy and/or tube insertion
Power Analysis:
 Sample size was selected to detect a difference in the rate of otorrhea of 10% or greater
from baseline of 16% with alpha = 0.05 and beta = 0.1.
Interventions
Group 1
 received three drops of Ciloxan (0.3% topical Ciprofloxacin hydrochloride) mixed with an
equal volume of 4% lidocaine placed into the external auditory canal immediately after
tube insertion
Group 2
 Received three drops of Cortisporin otic suspension (neomycin, Polymixin B and
Hydrocortisone) mixed with an equal volume of 4% lidocaine placed into the external
auditory canal immediately after tube insertion.
Both Groups
 same type of tube insertion technique and tubes
 Type of middle ear effusion noted after myringotomy was recorded
 Parents given a small bottle of drops without lidocaine and instructed to place 3 drops into
each ear 3 times a day for 3 days.
 If otorrhea persisted beyond 3 days parents were instructed to continue drops for 3 days
beyond end of drainage
 Information sheet was given to parents with usage instructions and brief description to
otorrhea symptoms. Parents contacted postoperatively by telephone to monitor for any
adverse effects and compliance.
 3 weeks postoperatively one investigator examined patient for evidence of otorrhea.
Outcomes

Primary Outcome:
 The rate of post-tympanostomy otorrhea
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Notes
Risk of bias table
Scholar’s
Judgment

Bias
Random sequence generation
(selection bias)

Low Risk

Allocation concealment (selection
bias)

Unclear Risk

Blinding of participants and
personnel (performance bias)

Low Risk

Blinding of outcome assessment
(detection bias)

Unclear Risk

Support for Judgment
Authors report double blinding
Not reported by authors
Blinding of ear drops for home (labeled A or B)
Not mentioned if telephone interviewer or investigator performing
final exam were blinded

Incomplete outcome data (attrition Unclear Risk
bias)

No incomplete outcome data reported.

Selective reporting (reporting bias) Low Risk

Outcomes reported

Nawasreh 2001
Methods
Participants

Parallel-group study (unclear if subjects were randomized or blinded)
Setting: Prince Rashid Ben Al-hasan hospital Jan 1999 - Aug 1999
Randomized into study: n = 88
 Group 1: ciprofloxacin n = 48
 Group 2: gentamicin n = 40
Completed study: n = 88
Gender, males: 46 (52%)
 Group 1: not reported
 Group 2: not reported
Age, years (mean): 9-62 (30)
 Group 1: not reported
 Group 2: not reported
Inclusion criteria: diagnosis of chronic suppurative otitis media; patients must have stopped
taking other medications 10 days prior to the start of treatment
Exclusion criteria: history of allergy to fluoroquinolone derivatives or aminoglycosides, < 9 yrs
of age, or past history of "general health problems"
Power Analysis: not discussed

Interventions

Subjects were divided into 2 groups:
 Group 1: ciprofloxacin 200 mcg/mL prepared by dissolving cipro HCl in distilled water
 Group 2: gentamicin sulfate 5 mg/mL
Both groups administered 5 drops in affected ear(s) 3 times daily for 10 days
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Outcomes

Primary Outcome Measures:
 cessation of otorrhea
 absence of microorganisms
 cure (higher is better)

Secondary Outcome Measures:
 hearing loss measured by "hearing levels and audio logical tests" before treatment and
24 hours after


Notes



Toxicity - no difference in "hearing levels or audio logical tests" between treatment
groups was noted
Clinical cure rate of cipro vs. gent favored cipro (p< 0.0001); however study has several
major limitations that call into question the generalizability of these results (see risk of
bias table)
o 6 patients in cipro group developed otomycosis (fungal infection) and were
considered treatment failures
o 12 patients in gentamicin group developed resistance during the course of
therapy
o actual cure rate for gentamicin based on susceptibility was 50%

Risk of bias table
Scholar’s
Judgment

Bias
Random sequence generation
(selection bias)

High Risk

Allocation concealment (selection
bias)

High Risk

Blinding of participants and
personnel (performance bias)

High Risk

Blinding of outcome assessment
(detection bias)

Unclear Risk

Incomplete outcome data
(attrition bias)

Low Risk

Support for Judgment
not discussed
not discussed
not blinded
unclear who performed outcome assessments and whether or not
they were blinded to patient treatment arm
data reported as expected (no missing data)

Selective reporting (reporting bias) Low Risk

pre-specified outcomes reported as expected

Other bias

baseline characteristics were not the same (no resistant bacteria
were identified in the cipro group; however, 16 of 40 subjects
were resistant in the gent group)

High Risk

Tong 1996
Methods
Participants

Double-blinded RCT
Setting: Specialist outpatient clinic in Hong Kong
Randomized into study: N = 52
 Group 1: ofloxacin n=28
 Group 2: neomycin-polymixin B-hydrocortisone n=24
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Completed Study: N = 52
 Group 1: ofloxacin n=28
 Group 2: neomycin-polymixin B-hydrocortisone n=24
Gender, males:
 Group 1: ofloxacin n= not provided
 Group 2: neomycin-polymixin B-hydrocortisone n=not provided
Age, years (mean):
 Group 1: ofloxacin n=not provided
 Group 2: neomycin-polymixin B-hydrocortisone n=not provided
Inclusion Criteria:
 patients exhibiting ororrhoea-associated recurent otitis media with tympanic perforations
Exclusion Criteria:
 Patients with history of sensitivity to any of the trial drugs
 Pregnant or lactating women
 Patients with tuberculosis, fungal, or viral diseases
 Patients with unsafe ears
 Patients who were unable to continue for the proposed length of treatment or return for
follow-up visits
Power Analysis: The authors did not disclose power analysis
Interventions

Outcomes

 Group 1: ofloxacin - Six drops twice daily
 Group 2: neomycin-polymixin B-hydrocortisone - Six drops twice daily
Patients were advised to apply the medication in a supine position with the target ear facing the
ceiling. Six drops of the medication were to be introduced into the external meatus at each
application. The tragus was massaged repeatedly and the same position maintained for 10
minutes. This was done twice daily for 14 days.
Primary outcomes:
 Symptomatic improvements
 Bacterial eradication
Safety outcome:
Adverse effects (Complications)

Notes

Symptom improvement:
 Group 1: ofloxacin
o Improvement: 25
o No improvement: 3
 Group 2: neomycin-polymixin B-hydrocortisone
o Improvement: 19
o No improvement: 5
Note: Bacterial eradication information was provided sorted by the type of bacteria present.
Since some ears had more than one type of bacteria present, the number below is different than
the total number of ears.
Bacterial Eradication:
 Group 1: ofloxacin
o Number of ears with bacteria eradicated at day 14: 25
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Total number of cases with that type of bacteria isolated at day 0: 31
(25/31=81%)
Group 2: neomycin-polymixin B-hydrocortisone
o Number of ears with bacteria eradicated at day 14: 24
o Total number of cases with that type of bacteria isolated at day 0: 32
(24/32=75%)
o



Risk of bias table
Scholar’s
judgment

Bias
Random sequence generation
(selection bias)

Low Risk

Allocation concealment (selection
bias)

Low Risk

Blinding of participants and
personnel (performance bias)

Low Risk

Blinding of outcome assessment
(detection bias)

Unclear Risk

Support for judgment
randomized
allocation was unclear, there were 3 participants excluded after
randomization (due to fungal infections) and the groups from
which they were removed was not disclosed
participants and personnel were blinded
not reported by authors

Incomplete outcome data (attrition Low Risk
bias)

attrition accounted for by authors

Selective reporting (reporting bias) Low Risk

no selective reported detected

Other bias

The study notes that the supply of ofloxacin otic solution supply
was provided by Daiichi Pharmaceutical company for the study.
The ages and genders of the participants were not disclosed

Unclear Risk

Tutkun 1995
Methods
Participants

Randomized Control Trial
Setting: Marmara University Hospital (Istanbul, Turkey) between November 1993 and June
1994.
Randomized into study: 44
Completed Study: 44
Gender, males (%):
 Group 1: Gentamicin - Not specified by the authors
 Group 2: Ciprofloxacin - Not specified by the authors
 Entire study: 23 (52)
Age, years (mean):
 Group 1: Gentamicin - Not specified by the authors
 Group 2: Ciprofloxacin - Not specified by the authors
 Entire Study: 9-65 (28)
Inclusion Criteria:
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 History of purulent otorrhea lasting more than 1 year
Exclusion Criteria:
 History of allergy to fluoroquinolone derivatives or aminoglycosides
 Younger than 9 years of age
 History of general health problems
 "Patients who did not use the topical solutions regularly and those who had taken any
other medication during the study period..."
Power Analysis: Not specified by the authors
Interventions

Group 1: 5 drops Gentamicin Sulfate (5 mg/mL) TID for 10 days
Group 2: 5 drops Ciprofloxacin (200 μg/mL) TID for 10 days



Outcomes
Notes

Cure Rate
Ototoxicity

Outcome:
 Ototoxicity - "There were no side effects, and audiometric evaluation yielded no evidence
of ototoxicity as reflected by the pure tone threshold and speech discrimination scores in
either group. The differences between pretreatment and postreatment."
All participants stopped all taking all medications 10 days prior to the treatment.

Risk of bias table
Bias

Scholar’s
Judgment

Random sequence generation
(selection bias)

Unclear Risk

Allocation concealment (selection
bias)

Unclear Risk

Blinding of participants and
personnel (performance bias)

Unclear Risk

Blinding of outcome assessment
(detection bias)

Unclear Risk

Incomplete outcome data
(attrition bias)

High Risk

Support for Judgment
Process for randomization not disclosed by the authors. "Patients
were randomly divided into two groups:..."
Process for allocation concealment not disclosed by the authors.
Blinding of participants and personnel not disclosed by the
authors.
Blinding of outcome assessment not disclosed by the authors.
Authors did not disclose the number of participants that were not
included in their results. Statement below is concerning that
incomplete data was presented in the publication.
"Patients who did not use the topical solutions regularly and those
who had taken any other medication during the study period..."

Selective reporting (reporting bias) Unclear Risk

All pre-specified outcomes are reported, however the protocol is
not available for further review.

Other bias

Unclear

Unclear Risk
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